REGENXBIO Duchenne Gene Therapy Meets Phase 3 Goal
The AFFINITY DUCHENNE gene therapy trial successfully hit its primary biomarker target in clinical testing.
Updated on Oct. 20, 2026 in Biotech
Live Poll
Do you trust medical findings based on early biomarker data before long-term disease outcomes are known?
REGENXBIO announced that its gene therapy candidate for Duchenne muscular dystrophy successfully increased microdystrophin protein levels above the required threshold in 93 percent of participants. Researchers observed these results 12 weeks after treatment in the Phase 3 clinical study.
Why it matters
The study utilized microdystrophin levels as a primary endpoint because the natural dystrophin gene is too large to be delivered by current viral vector carriers. This success brings the developer closer to potential regulatory approval for a condition that currently lacks a cure.
The trial involved 31 boys and required participants to achieve microdystrophin protein levels exceeding 10 percent of normal. Data indicated 93 percent of evaluable muscle samples successfully crossed this biomarker threshold by week 12.
The players
REGENXBIO
This is a clinical-stage biotechnology company that focuses on the development of gene therapy products based on its proprietary viral vector platform.
The details
The trial, which included 31 ambulatory boys, reported two serious drug-related adverse events, specifically heart muscle inflammation and asymptomatic liver injury, both of which resolved. Researchers measured protein levels via muscle biopsies, while functional scores were determined by comparing study participants against statistically weighted outside groups.
Timeline
May 2026: REGENXBIO announced topline trial results.
June 2026: The developer finished dosing for the confirmatory study.
October 16, 2026: NeurologyLive reported on the clinical trial results.
Second half of 2027: The company targets this window for possible FDA approval.
The Tech Race
The AFFINITY DUCHENNE gene therapy trial establishes a critical benchmark for using surrogate biomarkers in genetic medicine where traditional efficacy endpoints are difficult to measure. This development positions the treatment as a potential alternative to legacy supportive care methods currently used to manage muscular dystrophy.
While not yet available for clinical use, this progress indicates a potential future treatment option for families managing Duchenne muscular dystrophy. Patients and caregivers should monitor ongoing regulatory updates as the company pursues an FDA approval window for the second half of 2027.
The takeaway
This trial highlights the ongoing shift toward using measurable protein biomarkers to expedite the approval of treatments for rare genetic disorders. Families interested in such therapies should discuss the inclusion criteria of future randomized studies with their medical providers.
What happens next
REGENXBIO plans to initiate a randomized placebo-controlled study outside the U.S. in the first half of 2027.
Further reading
For broader context on how current genetic advancements are shaping medical development, read more in our Biotech section.
Source note: This article includes information reported by Medical Daily.
Live Poll
Do you trust medical findings based on early biomarker data before long-term disease outcomes are known?
